Enlivex Ltd. (NASDAQ:ENLV) Financings
Financings
| Raise | Date |
|---|---|
| Registered direct offering of ordinary shares (or pre-funded warrants) with accompanying ordinary warrants Announced: US$7.5M · US$1.315 a share · Warrants at US$1.578 for 36 months Use of proceeds: Clinical, regulatory, manufacturing and R&D activities; potential acquisitions and in-licensing; general corporate purposes | Nov 16, 2026 |
| Private placement of ordinary shares Cancelled: US$400M · US$6 a share Buyers: Rain Foundation (66,666,667 ordinary shares, to be paid for using RAIN tokens (agreement terminated)) Use of proceeds: Treasury strategy built around the Rain protocol prediction markets, while continuing to advance its Allocetra immunotherapy for age-related osteoarthritis | Sep 22, 2026 |
| Private placement of ordinary shares (or ordinary share equivalents) Closed: US$212M raised · US$1 a share · BTIG Dealers: BTIG (lead) Use of proceeds: Implement a RAIN prediction markets token treasury strategy while continuing core business operations | Nov 26, 2025 |